Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 05, 2026 16:45 ET | Source: Zealand Pharma

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity

Press release – No. 13 / 2026 New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...
June 05, 2026 11:48 ET | Source: EnGeneIC

EnGeneIC Honored with 2026 Breakthrough in Glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York

EnGeneIC Honored with 2026 Breakthrough in glioblastoma Biotech Award at Northwell Foundation Lenox Hill Neurosurgery Brain Cancer Gala in New York
June 05, 2026 10:05 ET | Source: Forbion

Forbion Expands Global Investment Leadership with Senior Promotions and Appointment of Operating Partner

Forbion announces the promotions of Jon Edwards, PhD, to General Partner, Regina Salvat, PhD, to Partner, and John McDonald, MBA, as Operating Partner.
June 05, 2026 08:30 ET | Source: Seegnal Inc.

Seegnal Accepted into Innovative Accelerator Program from AARP, the Largest U.S. Organization Serving Americans 50 and Older

CALGARY, AB, June 05, 2026 (GLOBE NEWSWIRE) -- Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a developer of innovative healthcare technology focused on mitigating medication risks, today...
June 04, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
June 04, 2026 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and...
June 04, 2026 03:00 ET | Source: Ona Therapeutics

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

Ona Therapeutics closes oversubscribed $86.6M Series B financing to advance first-in-class ADCs into clinical development for treatment-resistant cancers
June 03, 2026 09:28 ET | Source: 24/7 Market News

The Multi-Billion-Dollar Search for Better Glioblastoma Treatments

Yet one of oncology's greatest challenges, Glioblastoma, remains largely unsolved.
June 03, 2026 08:30 ET | Source: BioMedWire

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure,...
June 03, 2026 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...